

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



聯康集團

Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

VOLUNTARY ANNOUNCEMENT

MARKETING APPLICATION OF 金因康® (DIQUAFOSOL SODIUM EYE DROPS) HAS BEEN OFFICIALLY APPROVED BY THE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)

21 May 2025 — the board of directors (the “**Board**”) of Uni-Bio Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is delighted to announce that the China National Medical Products Administration (the “**NMPA**”) has approved the marketing application for the Group’s new ophthalmology product 金因康® (Diquafosol Sodium Eye Drops), with the approval number 「國藥准字H20254149」. 金因康®’s approval for marketing marks the further strengthening of the Group’s ophthalmology drug pipeline, providing dry eye syndrome patients with more diverse treatment options.

As the Group’s second ophthalmology drug following GeneSoft®, Diquafosol Sodium Eye Drops activates P2Y2 receptors to stimulate tear fluid and mucin secretion, addressing the underlying causes of dry eye syndrome, normalizing the tear layer and improving corneal epithelial damage, suitable for patients diagnosed with dry eye accompanied by abnormal tear-associated corneal epithelial defects, it represents the next generation of dry eye medication.

The Group’s new production facility in Dongguan deploys the latest Blow-Fill-Seal (BFS) technology with aseptic production process, coupled with preservative-free, single-dose packaging design. This advanced technology ensures enhanced pharmaceutical quality and dosing convenience. 金因康® is also projected to becoming one of the first BFS Diquafosol products approved for listing. Additionally, the Group has established strategic partnerships with Active Pharmaceutical Ingredient (API) suppliers, securing high-quality raw materials at costs well below industry averages. the Group has also strategically expanded its sales

* For identification purpose only

force and integrated online-offline channel resources, covering hospitals, pharmacies, and leading e-commerce platforms. These measures ensure rapid market penetration and competitiveness.

The number of patients with dry eye syndrome and market size continue to expand. Relevant data shows that there are approximately over 360 million patients in China, and the market size is projected to surpass RMB42 billion by 2030, growing at a CAGR of 28.4%. Furthermore, as patients increasingly prioritize treatment convenience and safety, 金因康® will provide a robust solution to address this widespread and underserved medical need.

Looking ahead, the approval of 金因康® is poised to create synergistic effects with GeneSoft®, driving sustained growth in the Group's performance. GeneSoft® aims for inclusion in medical insurance coverage by the end of 2025. More diversified sales channels and drug pipelines will enhance accessibility and market penetration of the Group's ophthalmic drugs and strengthen the Group's position in the ophthalmic market.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 21 May 2025

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang (Chief executive) and Dr. Wen Yalei (Chief Operating Officer); two non-executive Directors, Mr. Yau Kwok Wing Tony and Ms. Zhang Qing; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.